Candida
Organism in Candida that 1 drug acts on.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Rezafungin | Approved | Mundipharma | Small molecule | InhibitorCandida inhibitor | 4 |
| A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia | Rezafungin | — | Not yet recruiting | Augusta University | Apr 3, 2025 |
| Rezafungin for Treatment of Chronic Pulmonary Aspergillosis (CPA) in Adults With Limited Treatment Options | Rezafungin | Phase 2 | Active, not recruiting | Mundipharma Research Limited | Jan 27, 2025 |
| Rezafungin Prophylaxis in Liver Transplant | Rezafungin | Phase 3 | Enrolling by invitation | Fernanda P Silveira, MD, MS | Jan 14, 2025 |
| Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults | Rezafungin | Phase 2 | Recruiting | Mundipharma Research Limited | Apr 28, 2023 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL612867, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets